Oral supplementation with omega-3 fatty acids and inflammation markers in patients with chronic kidney disease in hemodialysis

Abstract

Chronic kidney disease (CKD) is an increasingly common public health problem that increases the risk of death due to cardiovascular complications by 2-3 times compared to the general population. This research concerns a prospective, randomized, double-blind study in patients with CKD undergoing hemodialysis. The participants were assigned to one of two groups: the study group (group A; 46 patients) received four capsules (2.4 g) of omega-3 fatty acids daily during the 12-week intervention, while patients in the control group (group B; 47 patients) received four capsules of paraffin oil. The patients’ general characteristics, nutritional indicators, renal disease markers and inflammatory markers (C-reactive protein, interleukin-6, interleukin-10 and tumour necrosis factor alpha) were evaluated. No differences were found between the general characteristics of the patients (P <0.05), and no differences were shown in the nutritional indicators and markers of kidney disease (P <0.05). Patients in group A showed significant decreases in levels of C-reactive protein, interleukin-6, tumour necrosis factor alpha and the interleukin-10/interleukin-6 ratio after 12 weeks of supplementation (P <0.05). Patients in group B did not show any significant changes in concentrations of inflammatory markers during the intervention (P <0.05). In conclusion, oral supplementation with omega-3 fatty acids produces a significant decrease in the concentrations of inflammation markers in patients with chronic kidney disease on hemodialysis.
 Novelty bullets:
 ●Oral supplementation with omega-3 fatty acids produced significant decreases in the concentrations of inflammation markers.
 ●This supplementation could be given to patients with uremic syndrome and coronary heart disease to reduce cardiovascular risk.

The effect of omega-3 fatty acids and vitamin E supplementation on lipid profiles and inflammatory markers in hemodialysis patients: A systematic review of current literature

“…Four capsules of omega-3 supplementation decrease CRP levels (11), however other studies showed the CRP level significant change is none (22,25). We found four articles which were evaluated CRP levels after vitamin E capsules administration in HD patients.…”

“…During this investigation, we extracted three articles which were evaluated CRP improvement after omega-3 administration (11,22,25). However, we found a particular study which was showed a significant difference after supplementation (11).…”

“…Omega-3 has many beneficial effects on the human body, especially in reducing inflammation in HD patients (11).…”

Effect of omega-3 fatty acids supplementation on homocysteine level in patients undergoing continuous ambulatory peritoneal dialysis

“…Another of the biomarkers of functional status, serum albumin, did not alter in the intervention group compared to the placebo, which is consistent with prior findings. [ 37 38 ] Gharekhani et al . [ 39 ] reported that omega-3 increased the serum level of albumin compared to the control group.…”

Dietary Lipids and Dyslipidemia in Chronic Kidney Disease

“…Raising blood ω-3 PUFA levels by fish oil supplementation significantly reduced C-reactive protein (CRP) levels in HD patients in a pilot study [ 96 ]. A more recent prospective randomized double-blind trial in CKD patients undergoing HD found that supplementation with 2.4 g/d of ω-3 PUFA for 12 weeks significantly lowered the levels of inflammatory markers such as CRP, interleukin-6 (IL-6), and tumor necrosis factor α (TNFα) [ 97 ]. The anti-inflammatory effect of ω-3 PUFA was confirmed for ESRD in a systematic review and meta-analysis of 13 RCTs that showed fish oil significantly decreased serum CRP and reduced cardiovascular events in patients on maintenance HD [ 98 ].…”